Glenmark Pharmaceuticals Limited (GLENMARK.BO)
INR 1541.0
(1.1%)
INR 1541.0
(1.1%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 11.34 Billion INR | -53.87% |
| 2022 | 11.58 Billion INR | 3.91% |
| 2021 | 22.26 Billion INR | 16.83% |
| 2020 | 21.79 Billion INR | 14.81% |
| 2019 | 18.9 Billion INR | 3.65% |
| 2018 | 15.85 Billion INR | 4.94% |
| 2017 | 17.06 Billion INR | -17.54% |
| 2016 | 20.73 Billion INR | 42.64% |
| 2015 | 14.47 Billion INR | 39.1% |
| 2014 | 10.44 Billion INR | -5.25% |
| 2013 | 11.02 Billion INR | 7.43% |
| 2012 | 10.2 Billion INR | 40.07% |
| 2011 | 7.32 Billion INR | -0.56% |
| 2010 | 7.36 Billion INR | 10.19% |
| 2009 | 6.68 Billion INR | 6.29% |
| 2008 | 5.12 Billion INR | -25.68% |
| 2007 | 8.46 Billion INR | 91.49% |
| 2006 | 4.41 Billion INR | 194.61% |
| 2005 | 1.5 Billion INR | -6.32% |
| 2004 | 1.6 Billion INR | 120.66% |
| 2003 | 725.73 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 5.88 Billion INR | -25.4% |
| 2023 FY | - INR | -53.87% |
| 2023 Q4 | 5.04 Billion INR | 408.96% |
| 2023 Q1 | 6.52 Billion INR | 16.33% |
| 2023 Q2 | 4.63 Billion INR | -28.85% |
| 2023 Q3 | -1.63 Billion INR | -135.18% |
| 2022 Q4 | 5.6 Billion INR | -19.53% |
| 2022 Q3 | 6.96 Billion INR | 23.23% |
| 2022 Q2 | 5.65 Billion INR | -8.04% |
| 2022 FY | - INR | 3.91% |
| 2022 Q1 | 6.14 Billion INR | 6.53% |
| 2021 Q3 | 7.07 Billion INR | 22.52% |
| 2021 Q2 | 5.77 Billion INR | -8.72% |
| 2021 Q1 | 6.32 Billion INR | 18.94% |
| 2021 Q4 | 5.77 Billion INR | -18.38% |
| 2021 FY | - INR | 16.83% |
| 2020 Q1 | 5.36 Billion INR | 5.01% |
| 2020 FY | - INR | 14.81% |
| 2020 Q2 | 5.2 Billion INR | -2.92% |
| 2020 Q3 | 5.45 Billion INR | 4.65% |
| 2020 Q4 | 5.31 Billion INR | -2.49% |
| 2019 Q3 | 4.73 Billion INR | -10.95% |
| 2019 Q4 | 5.11 Billion INR | 8.03% |
| 2019 FY | - INR | 3.65% |
| 2019 Q1 | 3.43 Billion INR | -14.66% |
| 2019 Q2 | 5.31 Billion INR | 54.62% |
| 2018 FY | - INR | 4.94% |
| 2018 Q1 | 4.85 Billion INR | 22.45% |
| 2018 Q3 | 3.25 Billion INR | -43.85% |
| 2018 Q2 | 5.79 Billion INR | 19.56% |
| 2018 Q4 | 4.02 Billion INR | 23.63% |
| 2017 Q3 | 2.99 Billion INR | -28.36% |
| 2017 FY | - INR | -17.54% |
| 2017 Q4 | 3.96 Billion INR | 32.26% |
| 2017 Q2 | 4.18 Billion INR | -29.47% |
| 2017 Q1 | 5.92 Billion INR | 50.99% |
| 2016 Q2 | 4.46 Billion INR | -1.78% |
| 2016 Q3 | 7.79 Billion INR | 74.43% |
| 2016 FY | - INR | 42.64% |
| 2016 Q4 | 3.92 Billion INR | -49.64% |
| 2016 Q1 | 4.54 Billion INR | 45.2% |
| 2015 FY | - INR | 39.1% |
| 2015 Q2 | 4.02 Billion INR | 10.31% |
| 2015 Q3 | 3.71 Billion INR | -7.62% |
| 2015 Q4 | 3.13 Billion INR | -15.74% |
| 2015 Q1 | 3.64 Billion INR | 29.54% |
| 2014 Q1 | 3.45 Billion INR | 127.48% |
| 2014 FY | - INR | -5.25% |
| 2014 Q4 | 2.81 Billion INR | 5.21% |
| 2014 Q3 | 2.67 Billion INR | -20.35% |
| 2014 Q2 | 3.36 Billion INR | -2.78% |
| 2013 Q4 | 1.52 Billion INR | -58.92% |
| 2013 FY | - INR | 7.43% |
| 2013 Q2 | 3.29 Billion INR | 31.05% |
| 2013 Q1 | 2.51 Billion INR | 0.53% |
| 2013 Q3 | 3.7 Billion INR | 12.45% |
| 2012 Q3 | 3.25 Billion INR | 17.06% |
| 2012 Q4 | 2.49 Billion INR | -23.21% |
| 2012 FY | - INR | 40.07% |
| 2012 Q1 | 1.67 Billion INR | -23.6% |
| 2012 Q2 | 2.77 Billion INR | 65.69% |
| 2011 Q4 | 2.19 Billion INR | 93.22% |
| 2011 FY | - INR | -0.56% |
| 2011 Q3 | 1.13 Billion INR | 0.0% |
| 2010 FY | - INR | 10.19% |
| 2009 FY | - INR | 6.29% |
| 2008 FY | - INR | -25.68% |
| 2007 FY | - INR | 91.49% |
| 2006 FY | - INR | 194.61% |
| 2005 FY | - INR | -6.32% |
| 2004 FY | - INR | 120.66% |
| 2003 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Ajanta Pharma Limited | 12.56 Billion INR | 9.723% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -1561.988% |
| Sigachi Industries Limited | 883.39 Million INR | -1184.098% |
| Bal Pharma Limited | 345.59 Million INR | -3182.397% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | -65.321% |
| Medico Remedies Limited | 150.37 Million INR | -7443.457% |
| Lasa Supergenerics Limited | -65.08 Million INR | 17530.393% |
| Venus Remedies Limited | 711.8 Million INR | -1493.662% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 404.017% |
| Alpa Laboratories Limited | 86.12 Million INR | -13070.899% |
| Nectar Lifesciences Limited | 1.56 Billion INR | -625.398% |
| Shilpa Medicare Limited | 2.58 Billion INR | -338.322% |
| Aarti Drugs Limited | 3.24 Billion INR | -249.184% |
| Lupin Limited | 36.96 Billion INR | 69.316% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 81.641% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 79.823% |
| Windlas Biotech Limited | 781.72 Million INR | -1351.121% |
| Suven Life Sciences Limited | -992.78 Million INR | 1242.62% |
| Eris Lifesciences Limited | 6.98 Billion INR | -62.367% |
| Valiant Laboratories Limited | 12.73 Million INR | -88947.021% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | -21.52% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 501.988% |
| Ipca Laboratories Limited | 13.29 Billion INR | 14.706% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -666.969% |
| Achyut Healthcare Limited | 524 Thousand INR | -2164728.244% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 91.802% |
| Bajaj HealthCare Limited | 444.51 Million INR | -2451.922% |
| RPG Life Sciences Limited | 1.28 Billion INR | -785.189% |
| Mankind Pharma Limited | 28.09 Billion INR | 59.623% |
| Laurus Labs Limited | 8 Billion INR | -41.69% |
| Piramal Pharma Limited | 13.05 Billion INR | 13.111% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -2536.378% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 67.598% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | -17.958% |
| Unichem Laboratories Limited | 742.35 Million INR | -1428.067% |
| Sequent Scientific Limited | 549.8 Million INR | -1963.241% |
| Novartis India Limited | 1.26 Billion INR | -793.697% |
| Wanbury Limited | 985.49 Million INR | -1051.072% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | -142.533% |
| Wockhardt Limited | 1.08 Billion INR | -950.343% |
| Themis Medicare Limited | 562.6 Million INR | -1916.274% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -3406.987% |
| Jubilant Pharmova Limited | 8 Billion INR | -41.69% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | -65.291% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 87.15% |
| Divi's Laboratories Limited | 25.43 Billion INR | 55.392% |
| NATCO Pharma Limited | 18.79 Billion INR | 39.645% |
| Gufic Biosciences Limited | 1.48 Billion INR | -666.215% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | -335.191% |
| Ind-Swift Limited | 1.06 Billion INR | -965.07% |
| Procter & Gamble Health Limited | 3.01 Billion INR | -276.317% |
| FDC Limited | 4.4 Billion INR | -157.712% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 13812.21% |
| Granules India Limited | 8.6 Billion INR | -31.845% |
| Medicamen Biotech Limited | 245.66 Million INR | -4517.642% |
| Alkem Laboratories Limited | 24.19 Billion INR | 53.116% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | -381.318% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -86745.047% |
| Brooks Laboratories Limited | 41.72 Million INR | -27084.864% |
| Megasoft Limited | 284.73 Million INR | -3884.006% |
| ZIM Laboratories Limited | 462.09 Million INR | -2354.831% |
| Strides Pharma Science Limited | 3.76 Billion INR | -201.319% |
| Neuland Laboratories Limited | 4.74 Billion INR | -138.906% |
| Morepen Laboratories Limited | 1.72 Billion INR | -557.242% |
| Hikal Limited | 2.69 Billion INR | -321.35% |
| Indoco Remedies Limited | 2.64 Billion INR | -328.541% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | -190.163% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -3846.664% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -6384.115% |
| Hester Biosciences Limited | 539.47 Million INR | -2002.749% |